1024033-43-9 Usage
General Description
AZD4017 is a novel and potent inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP) designed for the treatment of cancer. It works by blocking the PARP enzyme, which is responsible for repairing damaged DNA in cells. By inhibiting this enzyme, AZD4017 aims to prevent cancer cells from repairing their DNA, leading to their death. This makes it a promising candidate for combination therapy with DNA-damaging agents, such as chemotherapy, in the treatment of various types of cancer. Additionally, AZD4017 has shown potential in preclinical studies for the treatment of other diseases, such as inflammatory and neurodegenerative conditions. Further research and clinical trials are ongoing to evaluate its safety and efficacy in patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1024033-43-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,4,0,3 and 3 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1024033-43:
(9*1)+(8*0)+(7*2)+(6*4)+(5*0)+(4*3)+(3*3)+(2*4)+(1*3)=79
79 % 10 = 9
So 1024033-43-9 is a valid CAS Registry Number.
1024033-43-9Relevant articles and documents
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: Discovery of 2-[(3 s)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]- 3-piperidyl]acetic acid (AZD4017)
Scott, James S.,Bowker, Suzanne S.,Deschoolmeester, Joanne,Gerhardt, Stefan,Hargreaves, David,Kilgour, Elaine,Lloyd, Adele,Mayers, Rachel M.,McCoull, William,Newcombe, Nicholas J.,Ogg, Derek,Packer, Martin J.,Rees, Amanda,Revill, John,Schofield, Paul,Selmi, Nidhal,Swales, John G.,Whittamore, Paul R. O.
, p. 5951 - 5964 (2012/08/07)
Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. We report here the discovery of a nicotinic amide derived carboxylic acid class of inhibitors that has good potency, selectivity, and pharmacokinetic characteristics. Compound 11i (AZD4017) is an effective inhibitor of 11β-HSD1 in human adipocytes and exhibits good druglike properties and as a consequence was selected for clinical development.
